Clinical Report: HHS and FDA Praise DEA's Initiative to Regulate Hazardous Enhanced 7-OH Substances

Overview

The DEA has initiated the temporary scheduling of certain kratom-related substances, including 7-OH and its synthetic derivatives. This action follows recommendations from HHS and FDA based on scientific reviews of these substances.

Background

The regulation of kratom-related substances is due to their potential for addiction and harm. The recent actions by the DEA, HHS, and FDA aim to address the risks associated with enhanced levels of 7-OH and its synthetic derivatives.

Data Highlights

No numerical data or trial data presented in the source material.

Key Findings

• The DEA issued Notices of Intent to temporarily schedule 7-OH and three synthetic derivatives (MP, MGM-15, MGM-16).
• The scheduling action does not apply to natural kratom leaf containing only trace amounts of 7-OH.
• HHS Secretary Robert F. Kennedy, Jr. emphasized the dangers of 7-OH and its derivatives as addictive opioids.
• The FDA previously issued warning letters to companies marketing illegal products containing 7-OH.
• The temporary scheduling order can last for two years if deemed necessary to protect public safety.

Clinical Implications

Healthcare professionals should be aware of the regulatory changes regarding 7-OH and its derivatives.

Conclusion

The DEA's action to regulate 7-OH and its derivatives reflects a response to public health concerns.

Related Resources & Content

1. DEA, Press Release, 2026 -- DEA to Temporarily Schedule 7-OH and Related Substances to Protect Public Safety
2. The ASCO Post — FDA Approves Extended-Release, Single-Entity Hydrocodone Product With Abuse-Deterrent Properties
3. United States Department of Health and Human Services — HHS Launches MAHA Action Plan to Curb Psychiatric Overprescribing
4. The ASCO Post — USP Urged to Work With ASCO on Hazardous Drug Regulations
5. Ophthalmic Professional — COMPLIANCE
6. DEA to Temporarily Schedule 7-OH and Related Substances to Protect Public Safety
7. Safety and Tolerability of Single and Multiple Daily Oral Doses of Dried Kratom Leaf Powder in a Randomized Trial in Healthy Volunteers - PubMed
8. Kratom (Mitragyna speciosa) for pain management: a systematic review of preclinical evidence and limited clinical data - ScienceDirect